ReviewPulmonary circulation2026
Pulmonary Arterial Hypertension in Latin America: Characteristics, Treatment, and Survival From the LATAM-PAH Meta-Analysis and Systematic Review.
Review in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pulmonary arterial hypertension (PAH) in Latin America and the Caribbean (LAC) remains poorly characterized, with limited regional data on clinical presentation, hemodynamics, treatment patterns, and outcomes. We aimed to characterize demographic features, clinical presentation, hemodynamic severity, treatment patterns, and survival outcomes of right heart catheterization-confirmed PAH cohorts across LAC. We performed a systematic review and meta-analysis of retrospective and prospective cohort studies of adults with right heart catheterization-confirmed PAH in LAC, searching six databases in English, Spanish, and Portuguese without date restrictions. Study-level aggregate data were pooled using random-effects models. Sixteen studies from eight countries (1999-2025) including 2,553 patients were analyzed. Mean age was 43.6 years and 81.5% were female. Etiologies included idiopathic PAH (40.3%), congenital heart disease-associated PAH (25.6%), connective tissue disease-associated PAH (20.6%), and schistosomiasis-associated PAH (15.3% in Brazilian cohorts). At diagnosis, 51% were in functional class III/IV, mean 6-min walk distance was 406 m, mean pulmonary arterial pressure was 55.8 mmHg, and cardiac index was 2.63 L/min/m Trail Registration: PROSPERO CRD420251131636.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.